ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

RARE Ultragenyx Pharmaceutical Inc

42,75
-0,45 (-1,04%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Ultragenyx Pharmaceutical Inc RARE NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,45 -1,04% 42,75 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
44,88 42,675 46,005 42,75 43,20
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
02.5.202422:00GLOBEUltragenyx Reports First Quarter 2024 Financial Results and..
30.4.202422:00GLOBEUltragenyx Issues 2023 Corporate Responsibility Report,..
30.4.202414:00GLOBEUltragenyx Announces Completion of Enrollment in Phase 3..
25.4.202422:30GLOBEUltragenyx to Host Conference Call for First Quarter 2024..
19.4.202422:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
15.4.202413:00GLOBEUltragenyx Announces Positive Interim Phase 1/2 Data in..
12.4.202422:22GLOBEUltragenyx Announces Update to Conference Call Timing to..
12.4.202414:00GLOBEUltragenyx Announces Upcoming Data Presentations at American..
22.3.202421:00GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
06.3.202402:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202402:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202402:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202402:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202402:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202402:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202402:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.2.202422:30GLOBEUltragenyx to Participate at Investor Conferences in March
23.2.202422:05GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
21.2.202423:03EDGAR2Form S-3ASR - Automatic shelf registration statement of..
15.2.202422:04EDGAR2Form 8-K - Current report
15.2.202422:01GLOBEUltragenyx Reports Fourth Quarter and Full Year 2023..
08.2.202422:00GLOBEUltragenyx to Host Conference Call for Fourth Quarter and..
06.2.202414:00GLOBEUltragenyx Announces Data Demonstrating Treatment with UX111..
05.2.202422:05GLOBEUltragenyx Receives PRIME Designation from European..
25.1.202422:05GLOBEUltragenyx Announces Completion of Dosing Across Stage 1..
19.1.202422:00GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
08.1.202413:00GLOBEMereo BioPharma Provides Update on Pipeline Progress and..
08.1.202412:03EDGAR2Form 8-K - Current report
07.1.202417:00GLOBEUltragenyx Reports Preliminary 2023 Revenue; Guidance for..
04.1.202414:00GLOBEUltragenyx Receives Positive Recommendation from NICE in the..
03.1.202414:00GLOBEUltragenyx Announces Completion of Enrollment in Global..
02.1.202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.1.202422:05GLOBEUltragenyx to Present at the 42nd Annual J.P. Morgan..
21.12.202323:45DJNUltragenyx to Pay $6 Million to Settle Alleged False..
21.12.202322:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
21.12.202322:02EDGAR2Form 8-K - Current report
18.12.202314:00GLOBEUltragenyx Receives European Commission Decision for..
20.11.202322:30GLOBEUltragenyx to Participate at Investor Conferences in..
17.11.202322:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
07.11.202323:00GLOBEUltragenyx to Participate in the Jefferies London Healthcare..
02.11.202321:17EDGAR2Form 8-K - Current report
02.11.202321:05GLOBEUltragenyx Reports Third Quarter 2023 Financial Results and..
26.10.202322:05GLOBEUltragenyx to Host Conference Call for Third Quarter 2023..
23.10.202322:01GLOBEUltragenyx Announces Closing of Public Offering of Common..
23.10.202312:31EDGAR2Form 8-K - Current report
20.10.202322:00GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
20.10.202312:31EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19.10.202303:16GLOBEUltragenyx Announces Pricing of Public Offering of Common..
17.10.202322:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
17.10.202322:02GLOBEUltragenyx Announces Proposed Public Offering of Common..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock